Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUTCHMED (China) Limited 和黃醫藥(中國)有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 13)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached announcement which has been published by HUTCHMED (China) Limited on the website of the U.K. Regulatory Information Service on March 23, 2022.

By Order of the Board

Edith Shih

Non-executive Director and Company Secretary

Hong Kong, March 23, 2022

As at the date of this announcement, the Directors of the Company are:

Executive Directors:

Mr TO Chi Keung, Simon
(Chairman)
Dr Weiguo SU
(Chief Executive Officer and
Chief Scientific Officer)
Mr CHENG Chig Fung, Johnny
(Chief Financial Officer)

Non-executive Directors:

Dr Dan ELDAR Ms Edith SHIH

Independent Non-executive Directors:

Mr Paul Rutherford CARTER (Senior Independent Director) Dr Karen Jean FERRANTE Mr Graeme Allan JACK Professor MOK Shu Kam, Tony



2021 Annual Report and Notice of Annual General Meeting

Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, March 23, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:13) today announces that its 2021 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy ("AGM Materials") will be posted to shareholders on March 24, 2022 who have elected to receive the AGM Materials in printed form. The documents can also be accessed from the HUTCHMED website (www.hutch-med.com).

The 2022 Annual General Meeting ("AGM") will be held at the Conference Room, 18th Floor, Hutchison Telecom Tower, 99 Cheung Fai Road, Tsing Yi, Hong Kong on Wednesday, April 27, 2022 at 6:00 pm Hong Kong Time (11:00 am London Time).

To safeguard the health and safety of shareholders, HUTCHMED encourages shareholders to: (i) attend the AGM online and vote by means of electronic facilities; or (ii) exercise their right to vote at the AGM by appointing the Chairman of the AGM as their proxy. Shareholders will be able to view a live webcast of the AGM through the website of the Company at www.hutch-med.com/event/. All registered shareholders will also receive a letter containing log in details and information on how to access the webcast.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of about 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries

Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786

Media Enquiries

Americas – Brad Miles,+1 (917) 570 7340 (Mobile)Solebury Troutbmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

FTI Consulting <u>HUTCHMED@fticonsulting.com</u>

Asia – Zhou Yi, +852 9783 6894 (Mobile)
Brunswick HUTCHMED@brunswickgroup.com

Nominated Advisor

Atholl Tweedie / Freddy Crossley, +44 (20) 7886 2500 Panmure Gordon (UK) Limited